![Andrew Scharenberg](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Andrew Scharenberg
Vorstandsvorsitzender bei Umoja Biopharma, Inc.
Aktive Positionen von Andrew Scharenberg
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Umoja Biopharma, Inc.
![]() Umoja Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Umoja Biopharma, Inc. engages in the development of immunotherapy treatments for blood-based and organ-based tumors in adult and pediatric patients. It offers an integrated cellular immunotherapy platform comprising VivoVec in vivo delivery, RACR/CAR synthetic receptor payload and TumorTag targeting technologies that attack cancer cells. The company was founded by Michael Jensen, Philip Low, Andy Scharenberg and Ryan Crisman and is headquartered in Seattle, WA. | Vorstandsvorsitzender | - | - |
Gründer | - | - | |
Direktor/Vorstandsmitglied | - | 11.05.2022 | |
Vorsitzender | 11.05.2022 | 17.11.2022 | |
MPM BioImpact, Inc
![]() MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Private Equity Investor | 01.06.2019 | - |
Karriereverlauf von Andrew Scharenberg
Ehemalige bekannte Positionen von Andrew Scharenberg
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Casebia Therapeutics LLC
![]() Casebia Therapeutics LLC Pharmaceuticals: GenericHealth Technology Casebia Therapeutics LLC discovers, develops, and commercializes gene-editing therapeutics to treat the genetic causes of bleeding disorders and autoimmune disease. The joint venture company is based in Cambridge, MA. | Corporate Officer/Principal | 01.07.2017 | 01.08.2019 |
BLUEBIRD BIO, INC. | Berater | 01.07.2014 | 01.06.2017 |
Cellectis, Inc.
![]() Cellectis, Inc. Pharmaceuticals: MajorHealth Technology Part of Cellectis SA, Cellectis, Inc. engages in the upstream research of genome engineering and in the development of pre-engineered products for pharmaceutical industry, cell therapies, seed companies, and laboratory researchers. The company is based in New York, NY. André Choulika has been the CEO of the company since 2014. | Corporate Officer/Principal | 01.07.2011 | 30.06.2014 |
GENERATION BIO CO. | Gründer | 01.03.2017 | - |
Ausbildung von Andrew Scharenberg
UNC School of Medicine | Graduate Degree |
Statistik
International
Vereinigte Staaten | 8 |
Operativ
Founder | 2 |
Corporate Officer/Principal | 2 |
Director/Board Member | 1 |
Sektoral
Health Technology | 6 |
Finance | 2 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
BLUEBIRD BIO, INC. | Health Technology |
GENERATION BIO CO. | Health Technology |
Private Unternehmen | 4 |
---|---|
Umoja Biopharma, Inc.
![]() Umoja Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Umoja Biopharma, Inc. engages in the development of immunotherapy treatments for blood-based and organ-based tumors in adult and pediatric patients. It offers an integrated cellular immunotherapy platform comprising VivoVec in vivo delivery, RACR/CAR synthetic receptor payload and TumorTag targeting technologies that attack cancer cells. The company was founded by Michael Jensen, Philip Low, Andy Scharenberg and Ryan Crisman and is headquartered in Seattle, WA. | Health Technology |
Cellectis, Inc.
![]() Cellectis, Inc. Pharmaceuticals: MajorHealth Technology Part of Cellectis SA, Cellectis, Inc. engages in the upstream research of genome engineering and in the development of pre-engineered products for pharmaceutical industry, cell therapies, seed companies, and laboratory researchers. The company is based in New York, NY. André Choulika has been the CEO of the company since 2014. | Health Technology |
Casebia Therapeutics LLC
![]() Casebia Therapeutics LLC Pharmaceuticals: GenericHealth Technology Casebia Therapeutics LLC discovers, develops, and commercializes gene-editing therapeutics to treat the genetic causes of bleeding disorders and autoimmune disease. The joint venture company is based in Cambridge, MA. | Health Technology |
MPM BioImpact, Inc
![]() MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Finance |
- Börse
- Insiders
- Andrew Scharenberg
- Erfahrung